Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study

Immunotherapy has become a cornerstone for the treatment of renal cell carcinoma. Nevertheless, some patients are resistant to immune checkpoint inhibitors. The possibility to identify patients who cannot benefit from immunotherapy is a relevant clinical challenge. We analyzed the association betwee...

Full description

Bibliographic Details
Main Authors:	Ernesto Rossi, Luca Boldrini, Maria Grazia Maratta, Roberto Gatta, Claudio Votta, Giampaolo Tortora, Giovanni Schinzari
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	radiomics features renal cell carcinoma immunotherapy anti-pd-1 anti-ctla4 nivolumab ipilimumab pembrolizumab predictive factor
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2172926

Similar Items

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital
by: Ricardo Fernández-Ferreira, et al.
Published: (2019-12-01)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
by: Shantanu Banerji, et al.
Published: (2021-11-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma
by: Natasha Lakin, et al.
Published: (2017-07-01)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021-11-01)

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: Georgios Lyrarakis, et al.
Published: (2024-10-01)

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
by: Emily Z. Keung, et al.
Published: (2018-09-01)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
by: Melissa Bersanelli, et al.
Published: (2022-05-01)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
by: Trevor E. Angell, et al.
Published: (2018-03-01)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
by: Leanne Perez, et al.
Published: (2022-05-01)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
by: Ahmad Tarhini, et al.
Published: (2018-10-01)

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
by: Roy Herbst, et al.
Published: (2021-07-01)

Combatting mucosal melanoma: recent advances and future perspectives
by: Helen Tyrrell, et al.
Published: (2018-09-01)

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
by: Robert Roskoski, Jr.
Published: (2024-05-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
by: Sarabjot Pabla, et al.
Published: (2021-07-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

The use of immunotherapy in the treatment of melanoma
by: Tala Achkar, et al.
Published: (2017-04-01)

Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction
by: D. D. Sakaeva, et al.
Published: (2020-12-01)

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
by: Houssein Safa, et al.
Published: (2019-11-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01)

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
by: Yinghao Zhao, et al.
Published: (2018-05-01)

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
by: Qingyuan Huang, et al.
Published: (2018-12-01)

Some aspects of immunotherapy in colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2018-05-01)

Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
by: Johann Stuby, et al.
Published: (2020-11-01)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
by: Matthew D Biniakewitz, et al.
Published: (2021-01-01)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by: Carl Morrison, et al.
Published: (2018-05-01)

Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids
by: Maroun Sadek, et al.
Published: (2020-02-01)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
by: Forero Ivan, et al.
Published: (2012-05-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)